Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study
Authors
Keywords
-
Journal
Heliyon
Volume 9, Issue 5, Pages e15756
Publisher
Elsevier BV
Online
2023-04-25
DOI
10.1016/j.heliyon.2023.e15756
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rescue of multiple class II CFTR mutations by elexacaftor+ tezacaftor+ivacaftor mediated in part by the dual activities of Elexacaftor as both corrector and potentiator
- (2021) Onofrio Laselva et al. EUROPEAN RESPIRATORY JOURNAL
- Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry
- (2021) Graham L. Hall et al. EUROPEAN RESPIRATORY JOURNAL
- Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry Cohort study
- (2021) Edward F. McKone et al. EUROPEAN RESPIRATORY JOURNAL
- Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration
- (2021) Cameron B. Morrison et al. EUROPEAN RESPIRATORY JOURNAL
- A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants
- (2021) Guido Veit et al. Journal of Personalized Medicine
- Clinical Effectiveness of Elexacaftor/Tezacftor/Ivacaftor in People with Cystic Fibrosis
- (2021) David P Nichols et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung
- (2021) Lo M. Sosinski et al. Journal of Cystic Fibrosis
- Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis
- (2021) Max C. Petersen et al. Journal of Cystic Fibrosis
- Albumin/Globulin Ratio as Yin–Yang in Rheumatoid Arthritis and Its Correlation to Inflamm-Aging Cytokines
- (2021) Yong Chen et al. Journal of Inflammation Research
- Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi®) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
- (2020) Maria Favia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
- (2019) Harry G M Heijerman et al. LANCET
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
- (2019) Peter G. Middleton et al. NEW ENGLAND JOURNAL OF MEDICINE
- CORK Study in Cystic Fibrosis
- (2018) Nicola J. Ronan et al. CHEST
- Dysregulated Calcium Homeostasis in Cystic Fibrosis Neutrophils Leads to Deficient Antimicrobial Responses
- (2018) Frank H. Robledo-Avila et al. JOURNAL OF IMMUNOLOGY
- Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease
- (2018) Jinqiu Qin et al. Journal of Thoracic Disease
- Cystic fibrosis: current therapeutic targets and future approaches
- (2017) Misbahuddin M. Rafeeq et al. Journal of Translational Medicine
- Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor
- (2016) Preston E. Bratcher et al. Journal of Cystic Fibrosis
- Regulatory T-Cell Impairment in Cystic Fibrosis Patients with ChronicPseudomonasInfection
- (2015) Andreas Hector et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
- (2014) Steven M. Rowe et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor
- (2014) Sonya L. Heltshe et al. CLINICAL INFECTIOUS DISEASES
- A Th17- and Th2-skewed Cytokine Profile in Cystic Fibrosis Lungs Represents a Potential Risk Factor forPseudomonas aeruginosaInfection
- (2013) Kerstin Tiringer et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Immune Responses in Cystic Fibrosis
- (2012) Dmitry Ratner et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prevalence of cystic fibrosis in the European Union
- (2008) Philip M. Farrell Journal of Cystic Fibrosis
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started